Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Stock Swap -- Ignore unavailable to you. Want to Upgrade?

To: Grashopper who wrote (15849)	11/8/1998 6:42:00 PM
From: Andrew Vance	Read Replies (2) \| Respond to of 17305

AV--as a matter of fact, at current prices, both ATIS and PLSIA could be considered are worthwhile risks. The risk reward ration favors both stocks these days. You may not like this but both have a chance to be successful, both have a good chance to be pumped and dumped by the stock promoters, both are being hyped by boiler room compasnieis that still try to convince me this is a rocket to the moon, etc. Like GERN on Friday and ENMD earlier in the year, as examples, there is no way to stop herd mentality when it comes into play. There are a great deal of external influences and actions that can make both stocks very volatile. PLSIA's CEO was on CNBC on Friday morning and was very positive a bout her company. The delisting issue was rectified and the financial reporting issues resolved. On the STIS front, they did clear up their FDA standards of manufacturing issues and might be able to turn a corner. What I find interesting is that GERN looks to be a possibility of severe competition for ATIS and the competitors of ATIS, a few years down the road. Skin grafts might be the low of stuff that GERN would be involved in but you never know what could make the grade. GERN is too far off in the future to be a factor today. ATIS is trying to regain its reputation and confidence in the market. However, as much as both companies may be a worthwhile risk, I must re-iterate that most of the reasons have a great deal to do with "grey area" influences. Both stocks are easily manipulated, are favorites of the stock promoters and newsletters in certain circles, and have a great deal of people sitting on some expensive shares they want to unload. The products and capabilities seem to be overshadowed by these factors. I am commenting on these 2 companies in public but cannot, in all conscience, really recommend them as investment since there are many other stocks that are a good deal safer to invest in. I have 4 very risky stocks that I have taken small positions in as my own greedy gamble on moonshoots. One is almost up 3X in the past month, one is down 40%, the third is up 50% and the last is break even. All are $4 or less stocks and 3 trade under $2. If I cycle out of one of them profitably, I might consider getting into PLSIA or ATIS. Just keep in mind that their is a difference between investing and gambling. Andrew

To: Grashopper who wrote (15849)	11/9/1998 5:13:00 AM
From: Larry Brew	Respond to of 17305

Larry Boy, << here's my 1st peak at atis >> Attached is partial press release. Finding clients and clinics seems to be the gamble. Can they generate clinical interest/income??? I've boxed out 2 areas that get my attention, negatively that is. The Company will initially focus on a small number of centers, while working with the Health Care Financing Administration (HCFA) and other payors to address reimbursement. Under a Treatment IDE, companies are allowed to recover the costs of manufacturing and distributing the product. Advanced Tissue Sciences is a tissue engineering company utilizing its proprietary core technology to develop and manufacture human tissue products for tissue repair and transplantation. The Company, through its joint venture with Smith & Nephew plc, currently has two products on the market, TransCyte(TM) (formerly Dermagraft-TC(R)), for full and partial-thickness burns, and Dermagraft for the treatment of diabetic foot ulcers (currently available in Canada and the United Kingdom). In addition to TransCyte and Dermagraft, the Company is also developing products for cartilage and cardiovascular applications. --------------------------------------------------------------------- The matters discussed in this press release involve risks and uncertainties. In particular, the Company will need to successfully complete an additional controlled clinical trial of Dermagraft in the treatment of diabetic foot ulcers and submit a revised premarket approval application to the FDA. No assurance can be given that the Company will successfully complete the additional clinical trial, the ----------------------------------------------------------------- clinical trial will be completed within any specific timeframe, that the data from the trial will be statistically significant or otherwise consistent with the results of the Company's earlier pivotal trial or that the Company will obtain FDA or other regulatory approvals of Dermagraft (or that any such approvals will be obtained on a timely basis). In addition, there can be no assurance the ------------------------------------------------------------------- Company will successfully enroll centers and patients, or obtain adequate reimbursement, if any, under the Treatment IDE. These and --------------------------------------------------------- other risks are detailed in the Company's publicly available filings with the Securities and Exchange Commission including the Company's Annual Report on Form 10-K for the year ended December 31, 1997. Actual results may differ materially from those currently anticipated as a result of such risks. Larry